1.9.2023 Board Book

Product

Company/Organization Company Description

Type of Company

Board Member

Relationship

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio metabolic diseases. Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. Medical devices in major areas (e.g. cardiovascular, neurology, orthopedic) Minimally invasive – surgery technologies including robotics and tracking Medical equipment: therapeutic and diagnostic Health and personal Care products Medical IT and healthcare web applications Aesthetic-medical technologies Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California Anji Pharma is a clinical-stage biotech company with operations in the U.S., Beijing, and Shanghai. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Bionime was established in April 2003 with the goal of improving the lives of people with diabetes through better self-monitoring. Bionime is focused on designing and manufacturing accurate medical testing equipment. Boehringer Ingelheim is a pharmaceutical company that develops innovative healthcare products for both human & animal needs.

Biopharamaceutical

89Bio

Harold Bays

Received Grant, Consultant/Advisor

Allergan

Pharmacuetical

Harold Bays

Received Grant

Devices, therapeutics

Alon Medteck/Epitomee

Harold Bays

Received Grant

Altimmune

Biopharamaceutical

Harold Bays

Received Grant

Amgen

Biopharamaceutical

Harold Bays

Received Grant, Consultant/Advisor

Biotech

Anji Pharma

Harold Bays

Received Grant

AstraZeneca

Biopharamaceutical

Harold Bays

Received Grant

Axsome

Biopharamaceutical

Harold Bays

Received Grant

BioHaven

Biopharamaceutical

Harold Bays

Received Grant

Bionime

Biotechnology

Harold Bays

Received Grant

Biotechnology, Medical, Pharma ceutical

Boehringer Ingelheim

Harold Bays

Received Grant

CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases

CinCor

Biopharmaceutical

Harold Bays

Received Grant

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products Currax Pharmaceuticals LLC is a patient-first pharmaceutical company focused on the number one and number two preventable deaths in the United States: smoking addiction and obesity. Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products

CSL Behring

Biopharmaceutical

Harold Bays Ethan Lazarus Craig Primack

Received Grant

Speaker, Advisory Board

Speakers Bureau

Currax

Pharmacuetical

Anthony Auriemma

Speakers Bureau Received Grant Advisory Board

Harold Bays

Eli Lilly

Drug Manufacturers—General

Sandra Christensen

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule Evidera provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products. Gan & Lee Pharmaceuticals is a leading pharmaceutical company in China specializing in the development, production, and commercialization of recombinant insulin analogs and injection pens,* with plans to expand globally Gelesis is a biotechnology company developing first-in class therapeutics to safely treat obese, overweight, and diabetic patients. Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. Pfizer is a pharmaceuticals and biotechnology company. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Regerenron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with rare genetic diseases of obesity. Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

Esperion

Pharmacuetical

Harold Bays

Received Grant, Consultant/Advisor

Evidera

Biopharamaceutical, biotechnology

Harold Bays

Received Grant

Pharmaceuticals

Gan and Lee

Pharmacuetical

Harold Bays Craig Primack Angela Fitch

Received Grant Advisory Board Advisory Board

Biotechnology, Medical Device, diabetes

Gelesis

Sandra Christensen

Advisory Board

Madrigal

Biopharamaceutical

Harold Bays

Received Grant

Biopharamaceutical

Matinas

Harold Bays

Received Grant

Merck

Biotechnology, pharmaceutical

Harold Bays

Received Grant

New Amsterdam

Harold Bays

Received Grant

Novartis

Pharmacuetical

Harold Bays Harold Bays

Received Grant Received Grant Speakers Bureau Advisory Board Speakers Bureau

Sandra Christensen

Suzanne Cuda Ethan Lazarus

Biotechnology, pharmaceutical

NovoNordisk

Sylvia Gonshan-Bollie Anthony Auriemma

Consulting

Speakers Bureau

Biotechnology, pharmaceutical Harold Bays

Pfizer

Received Grant

Anthony Auriemma

Consulting

Phenomix

Biotechnology, pharmaceutical

Craig Primack

Advisor

Biotechnology

Regerenron

Harold Bays

Received Grant

Consultant in development of hyperphagia assessment tool

Ethan Lazarus

Rhythm Pharmaceuticals

Biotechnology, pharmaceutical

Suzanne Cuda

Gold Faculty

Sanofi

Pharmacuetical

Harold Bays

Received Grant

Biopharamaceutical

Satsuma

Harold Bays

Received Grant

Selecta Biosciences is a clinical stage biotechnology company with a commitment to solving the challenges associated with autoimmunity and unwanted immunogenicity through our pioneering ImmTOR® precision immune tolerance platform.

Biotechnology

Selecta

Harold Bays

Received Grant

Biopharamaceutical

VIVUS , Inc. is a biopharmaceutical company developing therapies for obesity, sleep apnea, diabetes and sexual health.

Anthony Auriemma

Speaker Bureau

Vivus

Biopharamaceutical

Harold Bays

Received Grant

Jenny Craig

Diet Program

Food and beverage

Angela Fitch

Science Advisory Board

Suvie builds a multi-zone cool to cook kitchen robot that makes 5 star meals with zero effort.

Food and beverage

Suvie

Angela Fitch

Advisor

Nutrition

Anthony Auriemma

Consulting

Nestlé Health Science is a leader in the field of nutritional science, committed to redefining the management of health. We offer an extensive portfolio of science-based consumer health, medical nutrition and supplement brands.

Nestle Nutrition

Food and beverage

Ethan Lazarus

Advisory Board/Speaker

Craig Primack

Co-Medical Director

Ms.Medicine is an innovative health care organization whose mission is to raise the standard of care of FoundHealth.com offers information to help patients discover a range of treatments for their health challenges Home Access Health Corporation, which is now a subsidiary of Everly Health, was founded to provide customers with health information through simple, self collected lab tests Metavante Technologies, Inc., through its subsidiary, Metavante Corporation, provided financial technology services, software and financial services regulatory advice and consulting to its customers, consisting Course and consulting business to help physicians start obesity medicine practices This course covers critical topics in the prevention and treatment of obesity and related disorders presented by authorities from the country’s leading obesity treatment centers. Practice Management Software Product sales in obesity medicine practice

Health Care

Angela Fitch

Advisory Board

MsMedicine

Health Care

Found Health

Angela Fitch

Advisory Board

Health Care

Home Access

Turn-Key Business Solutions

Harold Bays

Received Grant

Lexicon

Business Tools

Harold Bays

Received Grant

Shaklee Corporation

Health Care

Sylvia Gonshan-Bollie

Owner

Metavant

Business Tools

Harold Bays

Received Grant

Health Care

Weight Care Consulting

Carolynn Francavilla

Owner

Angela Fitch

Co-Director

Harvard Blackburn Obesity Medicine

Education

Ethan Lazarus

Presenter

Education

Medical educational company

Paradigm

Education

Craig Primack

Faculty

Continuing medical education (CME)

Pri-Med

Education Education

Craig Primack Harold Bays

CME Speaker Received Grant

An Academic Research Organization of Brigham &

TIMI

American College of Physicians (ACP)

Angela Fitch

American Academy of Pediatrics

Suzanne Cuda

Member

American Society of Metabolic and Bariatric Surgery (ASMBS)

Angela Fitch

Member

American Academy of Family Physicians Pediatric Endocrine Society (SIG)

Ethan Lazarus

Member

Marisa Censani Harold Bays Ethan Lazarus Suzanne Cuda Angela Fitch Craig Primack Sandra Christensen

Co-Chair

General Member, Fellow, Speaker

Member/Speaker General Member General Member

The Obesity Society (TOS)

General Member, planning committee

General Member

501C-6 / 501C-3 Organizations

National Lipid Association (NLA)

Harold Bays

Board Member, Fellow, Speaker

American Society of Preventative Cardiology (ASPC)

Harold Bays Harold Bays

Member, Fellow

The Endocrine Society

Member

American Association of Clinical Endocrinologists (AACE) American College of Cariology (ACC) American Medical Association (AMA) Washington Obesity Society American Diabetes Association (ADA)

Harold Bays

Member

Harold Bays Ethan Lazarus

Member, Fellow, Speaker Member, Delegate for OMA

Carolynn Francavilla

Governing Council for private practice physicians

Craig Primack

Member Member

Sandra Christensen

Harold Bays

Member

World Obesity Federation

Harold Bays

Member

Colorado Medical Society

Ethan Lazarus

Member

Illinois Obesity Society

Anthony Auriemma

Board of Trustee Member

Board of Trustees Meeting 01/09/2023

6:00-8:00 PM EST 5:00-7:00 PM CST 4:00-6:00 PM MST 3:00-5:00 PM PST

https://obesitymedicine-org.zoom.us/j/88530631804?pwd=VWV4aFNuSnFGdlFJOFNtZWNxQitPZz09

Presiding Officer: Angela Fitch, MD, FACP, FOMA, President

Time

Topic

Lead

Action

Doc#

Order

6:00 PM

Fitch

Call to Order, Opening Remarks

6:05 PM

Roll Call Conflict of Interest Disclosures

Censani

Update as necessary

1

6:08 PM

Approval of the Agenda Consent Agenda

Fitch

Vote

2-5

• Minutes 10/12/2022 • Items OMA has signed off on

Introduction of Lydia Haile, OMA Operations Specialist FY2023 Committee (Chairs & Membership) Approval FY2023 Budget Approval • OMA Leadership Attendance at other society’s meetings (EASO, TOS, ASMBS, etc.)

6:15 PM

Fraker

Information

6

6:20 PM

Fitch

Vote

Fraker Fitch

7-8

6:30 PM

Vote

6:45 PM Executive Committee (EC) Meeting Cadence for 2023 (4 th Thursday of each month @ 5:00 PM ET) Fitch

Information

6:50 PM

Treat & Refer Campaign Next Steps

Fitch, Primack

9-10

Information

• Grant acquisition for campaign from Eli Lilly or others (?) • OMA leading the development of OM Standards (?) • ASMBS’ Guidelines for Metabolic & Bariatric Surgery/Consensus Determination • National Board for Health & Wellness Coaching (NBHWC) Category I CPT Codes to the AMA

7:05 PM

OMA Items for Endorsement:

Fitch

11-13

Vote

14

7:20 PM Review of compensation survey from the Bariatric Medical/Surgical Committee

Shetye

General OMA Updates:

7:35 PM

Alexander

Information

• Maintaining AMA Delegate Seats + Membership Categories Subcommittee

Fitch

• Educational Programming Subcommittee

• Adult & Pediatric Obesity Algorithm Releases for 2023

Fraker, Freshwater, Cuda

15

Information

7:45 PM Updates from ASAE’s Exceptional Board Training (11/2022)

Fitch, Fraker

• Updating BOT orientation process & developing a BOT orientation handbook • Updating BOT ongoing training (re: professional development for BOT members) • Developing a single location for all BOT documents/resources • Update Nominating Process for Winter 2024’s cycle (actively seek leaders within OMA & asking them to run for BOT seats) • Monthly Updates to BOT &/or Membership from Fitch? • Adding a Generative Discussion as a standing item on each BOT Meeting Agenda

Discussion

7:55 PM

Old/New Business

Fitch

Adjourn

8:00 PM

Call to Adjourn and Closing Remarks

Fitch

Board of Trustees Meeting

October 12, 2022 1:00 PM--5:00 PM PT Anaheim, CA Marriott Hotel La Jolla/Los Angeles Meeting Room

Board of Trustees Meeting Minutes: October 12, 2022

Call to Order: The board meeting was called to order at 1:02 PM (PT) by Dr. Ethan Lazarus Roll Call: Dr. Harold Bays, Secretary/Treasurer Attendees : Drs . Craig Primack, Ethan Lazarus, Marisa Censani, Lydia Alexander, Ms. Sandra Christensen, Drs. Michelle Freshwater, Larry Richardson, Angela Fitch, Harold Bays, Anthony Auriemma, Suzanne Cuda, Bharti Shetye, Sylvia Gonsahn-Bollie, and Carolynn Francavilla Brown. Ms. Teresa Fraker (OMA Executive Director), Ms. Dana Stifter (OMA Operations and Governance Manager), and Mr. Jim Wilson (Legal Counsel). Introduction of new board member Dr. Sylvia Gonsahn-Bollie was introduced to the board as the newest Trustee. She will be officially installed during the OMA Installation of Officers on Friday, October 14, 2022, during the 2022 OMA Fall Conference.

Approval of Agenda Motion to accept the meeting agenda The motion passed Conflict of Interest Disclosures

Dr. Angela Fitch updated her disclosures to include that she is on the Advisory Board for Vivus. Dr. Suzanne Cuda updated her disclosures to include that she is on the Advisory Board and Speaker for Rhythm Pharmaceuticals. Dr. Carolynn Francavilla Brown updated her disclosures to include that she owns a small amount of stock in Eli Lilly. Dr. Bharti Shetye updated her disclosures to include membership in ASMBS and TOS. Sandra Christensen updated he disclosure to include membership in AANP.

1

Consent Agenda Extract pages 32-34 of the Consent Agenda which is documentation of the Current Obesity Codes Under ICD-10 and bring this material back to the board when ready/further clarification is needed on what action is to be taken on this document. Motion to accept the consent agenda The motion passed FOMA and MFOMA Policy Motion to approve Option #1 of the FOMA/MFOMA Policy with the edit of striking the word, “must” in the section that reads, “Candidates MUST meet two or more of the following requirements”. The motion passed Committees Ms. Dana Stifter reviewed the results from an OMA Staff survey on the 2022 Committees. The 2023 Board Liaisons for the OMA Committees will be as follows: • Advocacy Committee Liaisons will remain the same, Drs. Carolynn Francavilla Brown and Tony Auriemma • Bariatric Medical-Surgical Committee Liaison will remain the same, Dr. Bharti Shetye • Diversity, Equity, and Inclusion Committee Liaisons will be changed slightly to retain Ms. Sandra Christensen and Dr. Sylvia Gonsahn-Bollie will move from a membership role on this committee to now serve as a board liaison to this committee along with Ms. Sandra Christensen • Membership Committee will remain the same, Ms. Sandra Christensen and Dr. Lydia Alexander • Outreach Committee will remain the same, Doctors Lydia Alexander and Suzanne Cuda • Pediatric Committee will be changed slightly to retain Dr. Marisa Censani and Dr. Suzanne Cuda will move from a membership role on this committee to now serve as the board liaison to the committee along with Dr. Marisa Censani. The Speakers Bureau Task Force will be eliminated moving forward and will not continue in 2023, as their primary objectives have been met. Motion to change the name of the International and Diversity Committee to the Diversity, Equity, and Inclusion (DEI) Committee The motion passed Motion to create task force for the purposes of developing an OMA (educational) meeting planning task force to be led by Dr. Angela Fitch and she will appoint selected board members to this task force. The motion passed • CIT Education Committee Liaison will change to Dr. Sylvia Gonsahn-Bollie • CME Education Committee will remain the same, Dr. Michelle Freshwater

2

Obesity Pillars Journal Update Dr. Harold Bays gave an update on the success of the Obesity Pillars journal which included highlights of the journal whereby he reviewed the number of downloads and views, the relationship with the publisher (Elsevier), the number of reviewers, associate editors, time to decision for articles, review time of articles, training process for reviewers, top downloaded articles, and the inclusivity and diversity with the journal as well. Finance Committee Follow Up Dr. Harold Bays reviewed the work and follow-up items from the September 2022 meeting of the Finance Committee. Motion to approve the Investment Policy Statement The motion passed Ex-Officio Appointment to the Board Motion to approve Dr. Craig Primack as Ex-Officio member of the board Motion to table the NP/PA Membership Category discussion at the present time and instead proceed with an exploratory task force as noted below with findings presented at the next in person BOT Meeting in April of 2023 The motion passed A new task force will be created which will focus on Retaining AMA Seats in addition to examining Membership Categories will be chaired by Dr. Lydia Alexander and include the additional board members of Drs. Carolynn Francavilla Brown, Suzanne Cuda, Marisa Censani, Craig Primack, Tony Auriemma, and Ms. Sandra Christensen, all of whom have volunteered to serve on this task force. Relative to the edits and clarification in the OMA Bylaws as to the definition of a “term”, for the purpose of board service, in consultation with Mr. Jim Wilson, it was felt that a term will be defined by a two-year board seat; these edits are reflected in the OMA Bylaws as presented. It is felt that the “term” edits would not need to be presented to the OMA membership for a vote, but if there are proposed edits to the bylaws regarding the NP/PA Membership category (or other membership categories) based on the upcoming work of the task force as enumerated above, Mr. Jim Wilson advises that these changes be instituted at the same time in totality, particularly if any of the bylaw changes proposed would predicate presentation to the OMA membership for vote. Strategic Plan Implementation Motion to withdraw a total of $450,000 from the OMA financial investment reserves with an additional $50,000 permissible (for a total of $500,000) without board approval (if needed), to update the Association Management System (AMS) in addition to the other IT projects as outlined by Ms. Fraker (inclusive of the buildout of a marketing automation tool and a redesign of the OMA website). The motion passed The motion passed Executive Session NP/PA Membership Category

3

OMA Updates Ms. Fraker provided high level updates complimentary to the written narrative in the board materials relative to the departments of marketing, education, and membership. 2023 Board Meeting Dates The proposed 2023 board meeting dates (in-person as well as virtual) are as presented in the materials. Other than the in-person meetings, the virtual dates are TBD at present. Old/New Business New Business: Dr. Bharti Shetye shared that the OMA Bariatric Medical/Surgical Committee has done some preliminary work on a survey that they wish to deploy to the OMA membership examining Obesity Medicine (OM) Medical Director compensation as well as responsibilities of the OM Medical Directors across the country. It is recommended that Dr. Bharti Shetye forward the survey as an agenda item for review by the board in a future board meeting. Dr. Tony Auriemma spoke to the fact that NovoNordisk® recently sent out a company newsletter relative to upcoming obesity-related meetings where they mentioned the upcoming Obesity Week® meeting (11/2022) hosted by The Obesity Society (TOS), however, there was no mention in this newsletter regarding the upcoming OMA meetings. There seems to be potential opportunities to work toward building ongoing relationships with this (and other) organizations such that the OMA is viewed as a key partner and is equally represented accordingly. Dr. Angela Fitch also disclosed that effective 11/30/2022 she is changing jobs in that she will no longer be at the Massachusetts General Hospital (MGH) Weight Center, in Boston, MA and instead, she will be starting her own company as a co-founder and Chief Medical Officer which will focus to combine primary care as well as obesity treatment. The organization will be called Known Well Health.

Call to Adjourn and Closing Remarks Motion to adjourn the meeting at 5:04 PM PT Meeting is adjourned

4

November 9, 2022 Donna Pickett, MPH, RHIA Co-Chair, ICD-10-CM Coordination and Maintenance Committee National Center for Health Statistics

3311 Toledo Road, Room 2402 Hyattsville, Maryland 20782 Dear Ms. Pickett,

As members of the Obesity Care Advocacy Network (OCAN), we appreciate the opportunity to provide comments on the “Obesity in Children, Adolescents, and Adults” proposal considered at the September 2022 ICD-10 Coordination and Maintenance (C&M) meeting. Founded in 2015, OCAN is a diverse group of organizations focused on changing how we perceive and approach obesity in the U.S. OCAN works to increase access to evidence-based obesity treatments by uniting key stakeholders and the broader obesity community around significant education, policy and legislative efforts. We aim to fundamentally change how the U.S. healthcare system treats obesity, and to shift the cultural mindset on obesity so that policymakers and the public address obesity as a serious chronic disease. Obesity in Children, Adolescents, and Adults The ICD-10-CM codes for childhood and adult obesity lack the specificity needed for categorizing elevated BMI in children/adults. Furthermore, the current codes are stigmatizing and reflect outdated scientific understanding of the disease processes underlying obesity. OCAN strongly supports the proposal to update the ICD obesity codes presented by the CDC’s Division of Nutrition, Physical Activity, and Obesity, to address these issues at the 2022 Annual National Center for Health Statistics (NCHS) Coordination and Maintenance meeting. Current child and adult obesity codes in ICD-10 are clinically imprecise because they do not capture the nature of the disease process according to our current scientific understanding. For instance, diagnosing obesity “due to excess calories” reflects a simplistic understanding of energy balance that does not reflect the complex dysregulation in cellular homeostasis that contributes to obesity. A more appropriate term would be “energy imbalance.” Second, the current codes highlight alveolar hypoventilation and thereby ignores the spectrum of comorbidities associated with obesity. Third, the current codes do not accurately reflect the classification of obesity in either children or adults. The classification of obesity clinically begins with overweight and progresses through severe obesity. Accurate classification is important because the risk of morbidity and mortality increases as excess weight increases. Finally, the use of terms such as “morbid” and “due to excess calories” are pejorative and stigmatizing and blame the patient, rather than addressing the disease. Stigmatization, in turn, is associated with

reduced access to care and poorer health outcomes. Appropriate terms include “severe obesity” and the use of people first language (i.e., “individuals with obesity” as opposed to “obese individuals”). OCAN supports the proposed following modifications and additions to the current ICD-10 codes for obesity that will update pathophysiological understanding of obesity and uses preferred, stigma-free terminology: 1) Add new codes that reflect the current recognized BMI age- and gender specific percentile classification system for children and adolescents: • Overweight: BMI >85 th percentile to <95 th percentile for age and gender • Obesity: BMI >95 th percentile for age and gender • Severe obesity: BMI >120% of the 95 th percentile for age & gender 2) Add new codes that reflect the current recognized adult BMI categories: • Overweight: BMI 25-29.9 kg/m2

• Obesity Class I: BMI 30.0-34.9 kg/m2 • Obesity Class II: BMI 35.0-39.9 kg/m2 • Obesity Class III: BMI Above 40 kg/m2

3) Remove codes, clarifications or definitions that do not align with current knowledge or guidelines. Make clarifications to language that identifies excess calories as a cause of obesity. Consider adopting the language from the new ICD 11, “Obesity due to energy imbalance,” i.e.:

4)

Replace any mention of “morbid” obesity with severe obesity.

5)

Add new codes that allow for identification of obesity with comorbid conditions, including but not limited to: hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, non-alcoholic fatty liver disease, and depression.

Thank you again for the opportunity to provide comments on the proposed changes. Should you have any questions or require additional information, please feel free to contact any of us. The following members of OCAN support the proposed changes to the ICD-10-CM by the NCHS as outlined in the Topic Packet for the September 13-14, 2022 meeting. Sincerely, Academy of Nutrition and Dietetics American Academy of PAs American College of Occupational and Environmental Medicine American Gastroenterological Association American Society for Metabolic and Bariatric Surgery American Society for Nutrition ConscienHealth Diabetes Leadership Council Diabetes Patient Advocacy Coalition Endocrine Society Healthcare Leadership Council MedTech Coalition for Metabolic Health

National Council on Aging National Kidney Foundation Obesity Action Coalition Obesity Medicine Association Preventive Cardiovascular Nurses Association The Gerontological Society of America The Obesity Society The Sumner M. Redstone Global Center for Prevention and Wellness YMCA of the USA WW (WeightWatchers)

7173 S. Havana St #600-130 Centennial, CO 80112 P: 303.770.2526 | F: 303.779.4834 obesitymedicine.org

November 14, 2022 Donna Pickett, MPH, RHIA Co-Chair, ICD-10-CM Coordination and Maintenance Committee National Center for Health Statistics 3311 Toledo Road, Room 2402 Hyattsville, Maryland 20782 Dear Ms. Pickett,

On behalf of the more than 4,000 members of the Obesity Medicine Association (OMA), we are pleased to provide the following comments on the “Obesity in Children, Adolescents, and Adults” proposal considered at the September 2022 ICD-10 Coordination and Maintenance (C&M) meeting. The mission of the OMA is to empower our clinicians to provide compassionate, evidence-based obesity care through sustainable care models and we are confident that alterations to the ICD coding methodology for these patient groups will assist us in realizing this mission. Obesity in Children, Adolescents, and Adults The OMA is pleased to be a cosigner of the November 9, 2022, comments of the Obesity Care Advocacy Network (OCAN) and we support the coalition’s efforts to ensure that current and future ICD coding for childhood and adult obesity encompass the specificity needed for categorizing elevated BMI in children/adults. In addition, the OMA believes that the current codes are stigmatizing and reflect outdated scientific understanding of the disease processes underlying obesity. Therefore, we strongly support the proposal to update the ICD obesity codes as presented by the CDC’s Division of Nutrition, Physical Activity, and Obesity during the National Center for Health Statistics (NCHS) annual ICD-10 C&M meeting. It is imperative that the ICD-10 codes surrounding overweight and obesity are updated to capture the nature of the disease process according to the current scientific understanding. We must move away from simplistic rationales for diagnosing obesity such as “due to excess calories” and instead consider the complex dysregulation in cellular homeostasis that contributes to obesity. Therefore, using the term “energy imbalance” would be more appropriate. We are also troubled that the current codes do not encompass the full spectrum of comorbidities associated with obesity. There are more than 200 other chronic conditions associated with obesity-- including but not limited to: hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, non alcoholic fatty liver disease, and depression. Secondly, the current codes do not accurately reflect the classification of obesity in either children or adults. The classification of obesity clinically begins with overweight and progresses through severe obesity. Accurate classification is important because the risk of morbidity and mortality increases as excess weight increases. Finally, we must move away from further stigmatizing individuals affected by overweight or obesity. Use of person-first language is critical--referencing these individuals as overweight or obese results in patients feeling that they are defined by their disease. Using terms such as “morbid” and “due to excess

7173 S. Havana St #600-130 Centennial, CO 80112 P: 303.770.2526 | F: 303.779.4834 obesitymedicine.org

calories” are also stigmatizing and blame the patient, as opposed to truly addressing the scientific causes of this complex disease. Failure to address bias and stigma will only allow roadblocks to care to continue and result in poorer health outcomes. Again, the OMA appreciates this opportunity to share the above comments. Should you have any questions or need additional information, please feel free to contact me or our OMA Policy Consultant Christopher Gallagher at chris@potomaccurrents.com.

Sincerely

Angela Fitch, MD, FOMA, FACP President, Obesity Medicine Association (OMA)

OMA 2023 COMMITTEE ROSTERS

Diversity, Equity & Inclusion (DEI) Committee Chair: Dr. Monu Khanna BOT Liaisons: Sam Christensen & Dr. Sylvia Gonshan-Bollie OMA Staff Liaison: Alexa Medara Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Dr. Julie Magallanes Montone Dr. Malti Vij Dr. Sneha Mishra Dr. Pranjali Sharma

P

NJ

R

P P

OH AZ

N N

P

CO

R

Dr. Tiffani Bell Washington Dr. Thuyvan (Vanessa) Hoang

P

NC

N

P

TX

N

Dr. Jerome Puryear

P

OH

N

Dr. Melchor Paulo Aranas Natalie Conde, PA-C

P

IL

N

PA

FL

N

Dr. Tiffany Clayton Dr. Rajasree Nambron Dr. Reema Dbouk

P

NC

N

P

TX

N

P

GA

R

Dr. Nkemdilim Nwosa

P

FL

R

Dr. Smruti Nalawadi

P

CA

N

Dr. Courtney Whittle

P

GA

N

1 | P a g e

OMA 2023 COMMITTEE ROSTERS

Clinicians in Training (CIT) Committee Chair: Dr. Nick Pennings (2 nd year) BOT Liaison: Dr. Sylvia Gonshan-Bollie OMA Staff Liaisons: Joan Hablutzel & Janette Rickels Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Dr. Thuyvan Hoang Dr. Pascale Carbonara

P

TX

N

P

MA

N

Dr. Sara Karjoo

P

FL

N

Dr. Pranjali Sharma Dr. James Dombroski

P

CO

R

P

OH

N

Dr. Amal Othman

P

MI

R

Thomas George, DNP, FNP-C, NASM-CPT Cathleen McKnight, MS, DNP, CNP, NCMP, APRN Dr. Chowdhury Get Dr. Jeannette Ryan-Alkasab Dr. Jonathan Gabison Dr. Kimberly Bibb Dr. Jumana Antoun Dr. Gregory Dobhash

NP

MD

N

NP

OH

N

P

MA

N

P

MA

N

P

MI

N

P

MS

N

P

Beirut, Lebanon

N

P

PA

N

Dr. Monica Edwards

P

IL

N

Angela Golden, DNP, FNP-C,

NP

AZ

R

2 | P a g e

OMA 2023 COMMITTEE ROSTERS

FAANP, FOMA Dr. Mihir Patel Dr. Justin Tondt Dr. Daniel Maselli

P

MD

N

P

PA

R

P

GA

N

3 | P a g e

OMA 2023 COMMITTEE ROSTERS

Pediatric Committee Chair: Dr. Dominique Williams (2 nd year) BOT Liaison: Drs. Suzanne Cuda & Marisa Censani OMA Staff Liaisons: Debbie Robichaud Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Dr. Jacqueline Chan Dr. Rushika Conroy

P

GA

N

P

MA

R

Dr. Jennifer Paisley

P

IN

R

Dr. Amy Beck See at right

MO TN

N R

Pediatric Psychologist

Dr. Heather Champney Dr. Maribeth Orr Dr. Rashmi Dayal Dr. Evgenia Gourgari

P

P

KS

R

P

CA

N

P

D.C.

N

Dr. Allen Browne Dr. Amy Braddock Dr. Roohi Kharofa Dr. Manal Habib

P

ME

R

P

MO

R

P

OH

R

P

AZ

N

Cindi Condos, FNP

NP

CA

R

Dr. Allan Damian

P

WA

N

Dr. Mahmoud Hamdan Dr. Brooke Sweeney Nancy Browne, PPCNP-BC, FAANP, FAAN Dr. Vivienne Rose

P

WA

N

P

MO

N

NP

ME

R

P

MD

N

4 | P a g e

OMA 2023 COMMITTEE ROSTERS

Dr. Jimmell Felder Dr. Valerie O’Hara

P

SC

N

P

ME

R

5 | P a g e

OMA 2023 COMMITTEE ROSTERS

Outreach Committee Chair: Dr. Jennifer Ng (2 nd year) BOT Liaison: Drs. Suzanne Cuda & Lydia Alexander OMA Staff Liaisons: Katy Rudzinski Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Dr. Perminda Cabandugama

P

MO

R

Dr. Geetha Kamath Dr. Alina Elperin Dr. Shagun Bindlish

P

KS

R

P

IL

N

P

CA

R

Dr. Kimberley Sampson Nermeen Asham, RN Rachel Smith, DNP, FNP-C, CNM, NBC HWC Thomas George, DNP, FNP-C Chaka Brittain, NP Dr. Reema Dbouk Dr. Raphael Sepulveda Acosta Dr. Kanica Yashi Linzi Cruz, RDN, CSWOM, LDN, CDCES Dr. Anila Chadha

P

VT

R

See at right

MD

R

RN

NP

FL

N

NP

MD

N

P

CA

N

NP

FL

N

P

GA

R

P

CA

N

P

NY

R

See at right

TX

N

RD

Dr. Monu Khanna

P

MO

R

6 | P a g e

OMA 2023 COMMITTEE ROSTERS

CME Overview Committee Chair: Dr. Angela Golden (2 nd year) BOT Liaison: Dr. Michelle Freshwater OMA Staff Liaisons: Emma Blackwood Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Lori Wenz, NP-C, BC ADM Dr. Naomi Parrella Dr. Aparna Chandra

NP

CA

N

P

IL

R

P

OH

R

Dr. Allan Damian Dr. Nick Pennings

P

OR

N

P

NC

R

Dr. Mahesh Sreedasyam Dr. Tiffany Clayton Dr. Amit Algotar Dr. Hector Trevino Dr. Sadaf Mustafa Sharon Karp, PhD, MSN, APRN, CPNP-BC, FAANP

P

IN

R

P

NC

N

P

AZ

R

P

IN

N

P

MD

R

NP

TN

N

Dr. Komal Trivedi Dr. Amal Othman

P

MI

R

P

MI

R

Dr. Mahmoud Hamdan

P

WA

N

Dr. Mahtab Ahmed Dr. Leonid Kim

P

IA

R

P

WA

N

Dr. Allen Browne

P

ME

N

7 | P a g e

OMA 2023 COMMITTEE ROSTERS

Dr. Justin Tondt Dr. Shagun Bindlish Dr. Kabir Harricharan Singh Dr. Jennifer Paisley Dr. Komal Trivedi Dr. Jerome Puryear Dr. Nowreen Haq

P

PA

R

P

CA

N

P

TN

N

P

IN

N

P

MI

R

P

OH

N

P

MD

N

Dr. Mihir Patel

P

MD

N

Teresa Owens, FNP, FOMA

NP

CT

N

Dr. Mark Schwartz

P

NC

R

Roxanne Oliver, DNP, MOL, APRN, CPNP-PC, FAANP Dr. William McDaniel

NP

OH

N

P

GA

R

Dr. Kirsten Frederiksen

P

NV

R

Thomas George, DNP, FNP-C

NP

MD

N

8 | P a g e

OMA 2023 COMMITTEE ROSTERS

Membership Committee Chair: Dr. Kristopher Knoop (1 st year) BOT Liaisons: Sam Christensen & Dr. Lydia Alexander OMA Staff Liaisons: Christian DeSousa Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale

New (N) or returning (R) member?

Comments

Karli Burridge, PA, FOMA

PA

IL

R

Dr. Peter McIlveen Dr. Dafina Allen

P

NC

N

OB/GYN

P

MI

R

Dr. Teji Dhami

P

FL

R

Dr. Steven Teoh Dr. Kabir Harricharan Singh Dr. Stephanie Waisanen Dr. Abhijai Singh Ilka Moreno, FNP-C Dr. Leonid Kim Dr. Pranjali Sharma

P

Malaysia

R

P

TN

N

P

FL

N

P

WI

N

NP

AZ

N

P

WA

N

P

CO

N

Dr. Sejal Desai

P

TX

N

9 | P a g e

OMA 2023 COMMITTEE ROSTERS

Advocacy Committee 2023 Chair: Dr. Rebecca Andrick (2 nd year) OMA Advocacy Counsel: Chris Gallagher BOT Liaisons: Drs. Carolynn Francavilla-Brown & Anthony Auriemma OMA Staff Liaisons: E.J. Rickey Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA) Locale New (N) or returning (R) member? Comments

Dr. Laura Davisson

P

WV

R

Dr. Erik “Seth” Kramer

P

CO

R

Dr. Suzannah Luft Dr. Michael McClurkan Dr. Kimberley Sampson Allison Arends, NP Dr. Leslie Golden Dr. Rajasree Nambron

P

NH

N

Gastroenterologist/hepatologist

P

AR

R

P

VT

R

NP

MO

N

P

WI

R

P

TX

N

Dr. Vicki March

P

PA

R

Dr. Verlyn Washington Dr. Michelle Look

P

PA

R

P

CA

N

Dr. Cate Varney Dr. Dana Trippi

P

VA

R

P

NV

N

Dr. Yoon Ji (Jennifer) Ahn Dr. Chelsea Yost Dr. James Dombroski Emily Weaver, NP

P

MA

N

P

GA

N

P

OH

N

NP

NC

N

Dr. Kunal Agarwal

P

FL

N

10 | P a g e

OMA 2023 COMMITTEE ROSTERS

Bariatric Medical/Surgical Committee Chair: Dr. Christopher Weber (2 nd year) BOT Liaison: Dr. Bharti Shetye OMA Staff Liaison: Teresa Fraker Name Specialty (Physician=P, NP=Nurse Practitioner, Physician’s Assistant=PA)

Locale

New (N) or returning (R) member?

Comments

Dr. Elizabeth Fryoux Lori Wenz, NP Dr. Amanda Fontenot Dr. Kristopher Knoop Dr. Nowreen Haq Sue Benson Davies, PhD

P

MS

N

NP

CA LA

R N

P

P

TX

R

P

MD

N

See at right

SD

N

RD

Dr. Mahtab Ahmed

P

IA

R

Victoria (Tori) Butur, MSN, APRN, FNP-C

NP

IL

N

Dr. Kirsten Frederiksen

P

NV

R

Dr. Kevin Smith P

OK ME

N R N N

Dr. Laurie Han Dr. John Cleek

P P

SC

Rachel Fehl, FNP-C

NP

IL

11 | P a g e

2023 OMA Budget Worksheet

2022 Actuals thru Oct 2022

2023 Budget DRAFT Amounts

2021 Actuals

2022 Budget

2023 Notes:

Revenue Product Line:

Budget Line Items

2020 Budget

2020 Actuals

2021 Budget

Membership & Related Sales

This is based on a 10% increase over estimated YE2022. Potential membership type changes in 2023, but confident this will be met.

Membership Dues

$ $ $

1,274,000

$ $ $

1,077,117 130,000 1,207,117

$ $ $

1,235,000 100,000 1,335,000

$ $ $

1,186,296 100,000 1,286,296

$ $ $

1,243,670 115,000 1,358,670

$ $ $

1,129,801 120,000 1,249,801

$ $ $

1,503,355 120,000 1,623,355

Corporate Advisory Council

70,000

Total

1,344,000

Affliated Networking Groups

Dues

$ $ $ $ $

18,750 37,500 15,000 30,000 101,250

$ $ $ $ $

- - - - -

$ $ $ $ $

- - - - -

$ $ $ $ $

- - - - -

$ $ $ $ $

- - - - -

$ $ $ $ $

- - - - -

$ $ $ $ $

- - - - -

Education

Sponsorships & Advertisement

Exhibits

Total

Journal - JOMA (Obesity Pillars)

$

10,000

$

1,500

$

-

$

10,000

$

-

Education Products & Services

apparel, water bottles, rx pads, infographics

Merchandise Book Sales

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

35,000 20,000 750,000 25,000 20,000 35,000 40,000

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

38,871 19,456 574,924 30,541 8,850 64,005 33,387

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

35,000 20,400 589,050 29,800 8,400 56,338 31,975

$ $ $ $ $ $ $

78,948 15,119 858,455 56,344 11,700 74,141 53,634

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

69,000 11,350 790,000 55,300 12,000 33,500 25,250

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

48,315 18,977 680,052 61,121 11,900 43,808 27,061

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

52,000 24,200 825,000 63,100 15,200 28,600 42,000

speaker books, ABOM study books (purchased from publisher)

based on 2022 sales with slight increase Includes sales and collection of shipping charges

Digital CME (Academy)

Syllabus Sales

np/pa certificates. $100 each

Proficiency Badge and Certification Fees

sales will slow since no changes to SAP are schedule

SAP

Launching new version in late Jan 2023. Increased sales due to new launch

Algorithm Sales Webinars & Podcasts

5,000

144

90

550

-

- free for members, potential add of CME last Q 2022

Total

930,000

770,178

771,053

$

1,148,341

996,950

891,235

1,050,100

Spring Conference

Education Grants

20,000

2,500

20,000

$ $ $ $ $ $ $ $

21,500

20,000

20,000

20,000

Misc

-

-

-

-

-

-

-

Advertisements Sponsorships

1,050

3,300 11,700 60,000 381,750

1,200 11,490 18,900 370,838 423,928 -

2,700 40,000 95,000 420,000 100,000 677,700

3,225 43,453 109,280 389,492 153,815 719,265

2,000 53,000 119,000 450,000

10,000 40,000 130,000 600,000

-

Exhibits

4,200

600 paid @ $750 each

Registrations

283,288

Livestream Attendees

5,000

-

-

-

Total

805,000

291,038

476,750

644,000

Does not look like we budgeted for these until 2022 and came up quite a bit under so we are using a conservative estimate for FY2023 It's difficult to determine exactly how many members will apply for FOMA in any given year so will assume a conservative estimate for FY2023

Adminstration

Shipping

$

14,943

$

-

$

13,200

$

12,500.00

$

6,369

$

7,500.00

FOMA Application Fees

$ $

875 619

$ $

- -

$ $

2,000

$ $

1,500

$ $

5,000

$ $

2,000

Misc Income

314

-

257

-

$

16,437

$

-

$

15,514

$

14,000

$

11,626

$

9,500

Fall Conference

Educational Grants

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

20,000 5,000 4,500 85,000 150,000 930,000

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

-

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

20,000

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

41,500 8,269 7,834 32,506 95,080 295,733 143,370 624,292 28,115 12,690 11,300 15,500 67,605

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

20,000

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

41,500

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $

20,000

Misc..

900

-

-

-

-

Program Ads Sponsorships

3,480 15,135 19,655 347,368

5,500 17,600 90,000 643,750

2,700 30,000 80,000 420,000 100,000 652,700 29,960 9,000 15,500 10,000 64,460

6,225 38,822 111,388 228,027 129,400 555,361 24,650 4,980 4,875 14,000 48,505

2,000 46,000 83,000 300,000

Exhibits

400 paid $ 750 each

Registrations

Livestream Attendees

7,000

-

-

-

Total

1,201,500

386,538

776,850

451,000

Publications

Ads- Newsletter

50,000 50,000 35,000 10,000 145,000 50,000 16,500 79,200 25,000 170,700

14,500 9,430 17,500 3,000 44,430 59,740 11,892 60,354 17,405 149,391

19,900 11,400 27,000 5,000 63,300

23,620 12,000 9,000 15,000 59,620

Ads - Website/Social/Directory

Ads- Education Ads- Career Center

Total

Fundamentals Courses

Educational Grant Fundamentals Online

30,000

30,000

15,000

15,000

15,000

-

-

-

-

-

Average reg fee of $210.00 and average of 100 registration for 3 courses

Registrations

50,400 29,100 109,500

65,845 16,200 112,045

61,050 5,000 81,050

71,753 1,425 88,178

63,000

Exhibits

-

Total

78,000

New Projects/Innovations

Registrations

50,000 6,400

- - - -

50,000

10,633

- - - -

561

- -

Exhibits Grants

-

-

-

Pri-Med, Haymarket (already approved)

-

25,000 75,000

14,063 24,696

15,625 16,186

50,000 50,000

Total

56,400

Direct Public Support

Spring and Fall Sponsored Lunch

Corp Contrib for Education

$

-

$

90,000

$

90,000

$

50,000

$

90,000

$

100,000

$

90,000

Top Section Revenue total

$

4,753,850

$

2,955,128

$

3,707,453

$

3,754,217

$

3,921,530

$

3,690,156

$

4,046,075

top sections only - sub total

Total Revenue

$

4,753,850

$

2,955,128

$

3,707,453

$

3,754,217

$

3,921,530

$

3,690,156

$

4,046,075